Antiemetic use and chemotherapy induced nausea and vomitingrelated hospitalization costs after highly or moderately emetogenic chemotherapy

References

• Dranitsaris G , MolassiotisA, ClemonsMet al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann. Oncol.28(6), 1260–1267 (2017).
   PubMed Web of Science ®Google Scholar
• Lorusso D , BriaE, CostantiniA, DiMaio M, RostiG, MancusoA. Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life – an Italian survey. Eur. J. Cancer Care26(2), e12618 (2017).
   Web of Science ®Google Scholar
• Gupta K , WaltonR, KatariaSP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat. Res. Commun.26, 100278 (2021).
   PubMedGoogle Scholar
• Farrell C , BrearleySG, PillingM, MolassiotisA. The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support. Care Cancer21(1), 59–66 (2013).
   PubMed Web of Science ®Google Scholar
• Grabner M , PalliS, QuimboR, RugoH. The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag. Res.7, 175–188 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang L , LuS, FengJet al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving h. Ann. Oncol.29(2), 452–458 (2018).
   PubMed Web of Science ®Google Scholar
• Mosa ASM , HossainAM, LavoieBJ, YooI. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front. Pharmacol.11, 329 (2020).
   PubMed Web of Science ®Google Scholar
• Piechotta V , AdamsA, HaqueMet al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst. Rev.11(11), CD012775 (2021).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). (2020). www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
   Google Scholar
• Hesketh PJ , KrisMG, BaschEet al. Antiemetics: ASCO guideline update. J. Clin. Oncol.38(24), 2782–2797 (2020).
   PubMed Web of Science ®Google Scholar
• Roila F , MolassiotisA, HerrstedtJet al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol.27, v119–v133 (2016).
   PubMed Web of Science ®Google Scholar
• Navari RM . Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed. Res. Int.2015, 595894 (2015).
   PubMed Web of Science ®Google Scholar
• Aapro M , RuffoP, PanteriR, CostaS, PiovesanaV. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep.1(4), e1127 (2018).
   Google Scholar
• Clark-Snow R , AffrontiML, RittenbergCN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support. Care Cancer26(2), 557–564 (2018).
   PubMed Web of Science ®Google Scholar
• Dielenseger P , BorjesonS, VidallC, YoungA, JahnP. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support. Care Cancer27(11), 4099–4106 (2019).
   PubMed Web of Science ®Google Scholar
• Sommariva S , PongiglioneB, TarriconeR. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit. Rev. Oncol. Hematol.99, 13–36 (2016).
   PubMed Web of Science ®Google Scholar
• Scott JA , SchwarttzbergL, RoelandEJ, BinderG, GingrasL, NavariR. Avoiding acute care and unplanned hydrations from chemotherapy-induced nausea and vomiting (CINV) in real-world practice. J. Manag. Care Spec. Pharm.27(4-a Suppl.), S116 (2021).
   Google Scholar
• Burke TA , WisniewskiT, ErnstFR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support. Care Cancer19(1), 131–140 (2011).
   PubMed Web of Science ®Google Scholar
• Gralla RJ , BosnjakSM, HontsaAet al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol.25(7), 1333–1339 (2014).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ , RossiG, RizziGet al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann. Oncol.25(7), 1340–1346 (2014).
   PubMed Web of Science ®Google Scholar
• Navari RM , BinderG, BonizzoniE, Clark-SnowR, OlivariS, RoelandEJ. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol.17(23), 3027–3035 (2021).
   PubMed Web of Science ®Google Scholar
• Hata A , ShiraishiY, InuiNet al. Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase III study (CONSOLE). Oncol. Ther.10(1), 253–262 (2022).
   PubMed Web of Science ®Google Scholar
• RED BOOK Online . Micromedex Healthcare Series (2022). www.ibm.com/products/micromedex-red-book
   Google Scholar
• 2022 Q3 CMS payment schedule for injectable medications (2022). www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files
   Google Scholar
• 2022 CMS medicare fee schedule (2022) retreived from CMS, Centers for Medicare & Medicaid Services. (2022). www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched
   Google Scholar
• Botteman M , NickelK, CormanS, TuriniM, BinderG. Cost–effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support. Care Cancer28(2), 857–866 (2020).
   PubMed Web of Science ®Google Scholar
• Cawston H , BourhisF, ErikssonJet al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context6, 212298 (2017).
   PubMedGoogle Scholar
• Halloush S , AlhifanyAA, AlkhatibNSet al. Cost–effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin.38(4), 571–577 (2022).
   PubMed Web of Science ®Google Scholar
• Giuliani J , BonettiA. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. Expert Rev. Pharmacoecon. Outcomes Res.19(5), 505–508 (2019).
   PubMed Web of Science ®Google Scholar
• Erickson R , NebughrN, MosierMC, NibleyW. Hydration requirements in patients receiving highly emetogenic chemotherapy. Future Oncol.15(7), 753–761 (2019).
   PubMed Web of Science ®Google Scholar
• Roeland E , MaJ, BinderGet al. Hospitalization costs for nausea and vomiting: a savings opportunity. J. Clin. Oncol.35(Suppl. 31), 155–155 (2017).
   Web of Science ®Google Scholar
• Restelli U , SaibeneG, NardulliPet al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open7(7), e015645 (2017).
   PubMed Web of Science ®Google Scholar
• Park SH , BinderG, CormanS, BottemanM. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. J. Med. Econ.22(8), 840–847 (2019).
   PubMed Web of Science ®Google Scholar
• Dranitsaris G , MolassiotisA, ClemonsMet al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann. Oncol.28(6), 1260–1267 (2017).
   PubMed Web of Science ®Google Scholar
• Mosa ASM , RanaMKZ, IslamH, HossainA, YooI. A smartphone-based decision support tool for predicting patients at risk of chemotherapy-induced nausea and vomiting: retrospective study on app development using decision tree induction. JMIR Mhealth Uhealth9(12), e27024 (2021).
   PubMedGoogle Scholar